Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939
Hill NL, Mogle J, Bhargava S, Bell TR, Bhang I, Katz M, Sliwinski MJ. Longitudinal relationships among depressive symptoms and three types of memory self-report in cognitively intact older adults. Int Psychogeriatr. 2020 Jun;32(6):719-32. doi: 10.1017/S104161021900084X
Hill NL, McDermott C, Mogle J, Munoz E, DePasquale N, Wion R, Whitaker E. Subjective cognitive impairment and quality of life: a systematic review. Int Psychogeriatr. 2017 Dec;29(12):1965-77.
Luo C, Sun J, Liu D, Sun B, Miao L, Musetti S, Li J, Han X, Du Y, Li L, Huang L, He Z. Self-assembled redox dual-responsive prodrug-nanosystem formed by single thioether-bridged paclitaxel-fatty acid conjugate for cancer chemotherapy. Nano Lett. 2016 Sep 14;16(9):5401-8. doi: 10.1021/acs.nanolett.6b01632
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014 Oct 23;2014(6):437-49. doi: 10.2147/CMAR.S63603
Frye S, Crosby M, Edwards TP, Juliano R. US academic drug discovery. Nat Rev Drug Discov. 2011 Jun 1;10(6):409-10. doi: 10.1038/nrd3462
Hegarty AC, Carsin AE, Comber H. Geographical analysis of cancer incidence in Ireland: comparison of two bayesian spatial models. Cancer Epidemiol. 2010 Aug;34(4):373-81. doi: 10.1016/j.canep.2010.04.019